Pulse Explore Journal Club Debates Trending Researchers Journals

Home Explore Journal Club Trending

⌘+K

Landmark trial may herald new era in HIV prevention | Synapse

August 1, 2024Science1 citationsOpen Access

Landmark trial may herald new era in HIV prevention

View Full Paper

KKKai Kupferschmidt

Key Points

Key points are not available for this paper at this time.

Abstract

Twice-yearly lenacapavir injections provide 100% protection in study in African women

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Kai Kupferschmidt (2024) studied this question.

synapsesocial.com/papers/68e5dd9eb6db643587573830 https://doi.org/https://doi.org/10.1126/science.ads1310

Ask AI

Helpful

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women2024 · 485 citations
2Lenacapavir: a transformative advance in HIV therapy and prevention—promise, access, and equity in Africa2026
3Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind2026 · 5 citations
4Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir2026 · 1 citations
5Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention2026